ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Program Review: Report calls For Two Types Of Centers: Comprehensive And All Others

October 18, 1996

Laertrile Clinical Study Provides Solid Evidence: It Is Useless

May 8, 1981

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

NCI T Use Ames Test In Carcinogenesis Testing Program

December 3, 1976

Oncology Societies, Cancer Center, List Reform Principles

August 12, 1994

NCI Funded Over 4,500 Grants Last Year, Half Its $3B Budget.

January 19, 2001